The incretin effect in type 2 diabetes in a Sub-Saharan African population.

Clinical Diabetes and Endocrinology Pub Date : 2024-07-25 DOI:10.1186/s40842-024-00178-5

Signe Tellerup Nielsen, Belinda Kweka, George Praygod, Suzanne Filteau, Mette Frahm Olsen, Henrik Friis, Daniel Faurholt-Jepsen, Rikke Krogh-Madsen

{"title":"The incretin effect in type 2 diabetes in a Sub-Saharan African population.","authors":"Signe Tellerup Nielsen, Belinda Kweka, George Praygod, Suzanne Filteau, Mette Frahm Olsen, Henrik Friis, Daniel Faurholt-Jepsen, Rikke Krogh-Madsen","doi":"10.1186/s40842-024-00178-5","DOIUrl":null,"url":null,"abstract":"Aim: Type 2 diabetes is increasing in Sub-Saharan Africa, but the pathophysiology in this population is poorly investigated. In Western populations, the incretin effect is reduced in type 2 diabetes, leading to lowered insulin secretion. The aim of this study was to investigate the incretin effect in a group of Sub-Saharan Africans with type 2 diabetes.Methods: Twenty adults diagnosed with type 2 diabetes, based on either an oral glucose tolerance test (n = 10) or on glycated hemoglobin A1c (n = 10), and 10 non-diabetic controls were included in an interventional study in Tanzania. We investigated the incretin effect as the difference between the plasma insulin area under the curve during an oral glucose tolerance test and that obtained during an intravenous glucose infusion. Differences between diabetes groups were analyzed by Kruskal-Wallis one-way analysis of variance.Results: The incretin effect did not differ between groups (p = 0.45), and there was no difference in plasma concentrations of the incretin hormones during the OGTT.Conclusion: A reduced incretin effect appears not to contribute to hyperglycemia in type 2 diabetes in this Tanzanian population. More research is needed to explain the diabetes phenotype often seen in Sub-Saharan Africa.Trial registration: Clinicaltrials.gov: NCT03106480 , date of registration: 04/10/2017.","PeriodicalId":56339,"journal":{"name":"Clinical Diabetes and Endocrinology","volume":"10 1","pages":"20"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes and Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40842-024-00178-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Type 2 diabetes is increasing in Sub-Saharan Africa, but the pathophysiology in this population is poorly investigated. In Western populations, the incretin effect is reduced in type 2 diabetes, leading to lowered insulin secretion. The aim of this study was to investigate the incretin effect in a group of Sub-Saharan Africans with type 2 diabetes.

Methods: Twenty adults diagnosed with type 2 diabetes, based on either an oral glucose tolerance test (n = 10) or on glycated hemoglobin A1c (n = 10), and 10 non-diabetic controls were included in an interventional study in Tanzania. We investigated the incretin effect as the difference between the plasma insulin area under the curve during an oral glucose tolerance test and that obtained during an intravenous glucose infusion. Differences between diabetes groups were analyzed by Kruskal-Wallis one-way analysis of variance.

Results: The incretin effect did not differ between groups (p = 0.45), and there was no difference in plasma concentrations of the incretin hormones during the OGTT.

Conclusion: A reduced incretin effect appears not to contribute to hyperglycemia in type 2 diabetes in this Tanzanian population. More research is needed to explain the diabetes phenotype often seen in Sub-Saharan Africa.

Trial registration: Clinicaltrials.gov: NCT03106480 , date of registration: 04/10/2017.

查看原文本刊更多论文

撒哈拉以南非洲人群中 2 型糖尿病的增量素效应。

目的：2 型糖尿病在撒哈拉以南非洲地区呈上升趋势，但对这一人群的病理生理学研究甚少。在西方人群中，2 型糖尿病患者的胰岛素增量效应降低，导致胰岛素分泌减少。本研究旨在调查一组撒哈拉以南非洲 2 型糖尿病患者的增量素效应：坦桑尼亚的一项干预研究纳入了根据口服葡萄糖耐量试验（10 人）或糖化血红蛋白 A1c（10 人）诊断为 2 型糖尿病的 20 名成人和 10 名非糖尿病对照者。我们用口服葡萄糖耐量试验期间的血浆胰岛素曲线下面积与静脉注射葡萄糖期间的血浆胰岛素曲线下面积之间的差异来研究增量素效应。糖尿病组之间的差异通过 Kruskal-Wallis 单因素方差分析进行分析：结果：增量素效应在不同组间没有差异（p = 0.45），在口服葡萄糖耐量试验期间，增量素激素的血浆浓度也没有差异：结论：在这一坦桑尼亚人群中，增量素效应降低似乎并不是导致 2 型糖尿病患者出现高血糖的原因。要解释撒哈拉以南非洲常见的糖尿病表型，还需要更多的研究：试验注册：Clinicaltrials.gov：NCT03106480 ，注册日期：04/10/2017.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Diabetes and Endocrinology

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Diabetes and Endocrinology is an open access journal publishing within the field of diabetes and endocrine disease. The journal aims to provide a widely available resource for people working within the field of diabetes and endocrinology, in order to improve the care of people affected by these conditions. The audience includes, but is not limited to, physicians, researchers, nurses, nutritionists, pharmacists, podiatrists, psychologists, epidemiologists, exercise physiologists and health care researchers. Research articles include patient-based research (clinical trials, clinical studies, and others), translational research (translation of basic science to clinical practice, translation of clinical practice to policy and others), as well as epidemiology and health care research. Clinical articles include case reports, case seminars, consensus statements, clinical practice guidelines and evidence-based medicine. Only articles considered to contribute new knowledge to the field will be considered for publication.